公开(公告)号：US20110130998A1

公开(公告)日：2011-06-02

申请号：US13024076

申请日：2011-02-09

申请人： Paul V. Goode, JR. ,  James H. Brauker ,  Apurv U. Kamath ,  James Patrick Thrower ,  Victoria Carr-Brendel

发明人： Paul V. Goode, JR. ,  James H. Brauker ,  Apurv U. Kamath ,  James Patrick Thrower ,  Victoria Carr-Brendel

IPC分类号： G06F19/00 ,  G01N33/48

CPC分类号： A61B5/7203 ,  A61B5/0004 ,  A61B5/0031 ,  A61B5/14532 ,  A61B5/14539 ,  A61B5/14542 ,  A61B5/1473 ,  A61B5/14865 ,  A61B5/1495 ,  A61B5/7225 ,  A61B5/7257 ,  A61B5/726 ,  A61B5/7278 ,  A61B5/742 ,  A61B5/7475 ,  A61B2560/0223 ,  A61B2562/0247 ,  A61B2562/0271 ,  A61B2562/08

摘要： Systems and methods for minimizing or eliminating transient non-glucose related signal noise due to non-glucose rate limiting phenomenon such as ischemia, pH changes, temperatures changes, and the like. The system monitors a data stream from a glucose sensor and detects signal artifacts that have higher amplitude than electronic or diffusion-related system noise. The system replaces some or the entire data stream continually or intermittently including signal estimation methods that particularly address transient signal artifacts. The system is also capable of detecting the severity of the signal artifacts and selectively applying one or more signal estimation algorithm factors responsive to the severity of the signal artifacts, which includes selectively applying distinct sets of parameters to a signal estimation algorithm or selectively applying distinct signal estimation algorithms.

公开(公告)号：US07935057B2

公开(公告)日：2011-05-03

申请号：US12353799

申请日：2009-01-14

申请人： Paul V. Goode, Jr. ,  James H. Brauker ,  Apurv U. Kamath ,  James Patrick Thrower ,  Victoria Carr-Brendel

发明人： Paul V. Goode, Jr. ,  James H. Brauker ,  Apurv U. Kamath ,  James Patrick Thrower ,  Victoria Carr-Brendel

IPC分类号： A61B5/00 ,  A61B5/05

CPC分类号： A61B5/7203 ,  A61B5/0004 ,  A61B5/0031 ,  A61B5/14532 ,  A61B5/14539 ,  A61B5/14542 ,  A61B5/1473 ,  A61B5/14865 ,  A61B5/1495 ,  A61B5/7225 ,  A61B5/7257 ,  A61B5/726 ,  A61B5/7278 ,  A61B5/742 ,  A61B5/7475 ,  A61B2560/0223 ,  A61B2562/0247 ,  A61B2562/0271 ,  A61B2562/08

摘要： Systems and methods for minimizing or eliminating transient non-glucose related signal noise due to non-glucose rate limiting phenomenon such as ischemia, pH changes, temperatures changes, and the like. The system monitors a data stream from a glucose sensor and detects signal artifacts that have higher amplitude than electronic or diffusion-related system noise. The system replaces some or the entire data stream continually or intermittently including signal estimation methods that particularly address transient signal artifacts. The system is also capable of detecting the severity of the signal artifacts and selectively applying one or more signal estimation algorithm factors responsive to the severity of the signal artifacts, which includes selectively applying distinct sets of parameters to a signal estimation algorithm or selectively applying distinct signal estimation algorithms.

摘要翻译： 用于最小化或消除由于非葡萄糖速率限制现象（如缺血，pH变化，温度变化等）引起的瞬时非葡萄糖相关信号噪声的系统和方法。 系统监测来自葡萄糖传感器的数据流，并检测具有比电子或扩散相关系统噪声更高的幅度的信号伪像。 该系统连续地或间歇地替代一些或整个数据流，包括特别地解决瞬态信号伪影的信号估计方法。 该系统还能够检测信号伪像的严重性并且响应于信号伪像的严重性选择性地应用一个或多个信号估计算法因子，其包括选择性地将不同的参数集合应用于信号估计算法或选择性地应用不同信号 估计算法。

公开(公告)号：US07914450B2

公开(公告)日：2011-03-29

申请号：US12772849

申请日：2010-05-03

申请人： Paul V. Goode, Jr. ,  James H. Brauker ,  Apurv U. Kamath ,  Victoria Carr-Brendel

发明人： Paul V. Goode, Jr. ,  James H. Brauker ,  Apurv U. Kamath ,  Victoria Carr-Brendel

IPC分类号： A61B5/00

CPC分类号： A61B5/1495 ,  A61B5/14532 ,  A61B5/14542 ,  A61B5/14865 ,  A61B2560/0223 ,  G06F19/00

摘要： Systems and methods for processing sensor analyte data, including initiating calibration, updating calibration, evaluating clinical acceptability of reference and sensor analyte data, and evaluating the quality of sensor calibration. During initial calibration, the analyte sensor data is evaluated over a period of time to determine stability of the sensor. The sensor may be calibrated using a calibration set of one or more matched sensor and reference analyte data pairs. The calibration may be updated after evaluating the calibration set for best calibration based on inclusion criteria with newly received reference analyte data. Fail-safe mechanisms are provided based on clinical acceptability of reference and analyte data and quality of sensor calibration. Algorithms provide for optimized prospective and retrospective analysis of estimated blood analyte data from an analyte sensor.

公开(公告)号：US20100234796A1

公开(公告)日：2010-09-16

申请号：US12788125

申请日：2010-05-26

申请人： Apurv U. Kamath ,  Paul V. Goode, JR. ,  James H. Brauker ,  Victoria Carr-Brendel

发明人： Apurv U. Kamath ,  Paul V. Goode, JR. ,  James H. Brauker ,  Victoria Carr-Brendel

IPC分类号： A61M37/00 ,  G06F19/00 ,  G01N33/48

CPC分类号： A61B5/1495 ,  A61B5/14532 ,  A61B5/14542 ,  A61B5/14865 ,  A61B2560/0223 ,  G06F19/00

摘要： Systems and methods for processing sensor analyte data, including initiating calibration, updating calibration, evaluating clinical acceptability of reference and sensor analyte data, and evaluating the quality of sensor calibration. During initial calibration, the analyte sensor data is evaluated over a period of time to determine stability of the sensor. The sensor may be calibrated using a calibration set of one or more matched sensor and reference analyte data pairs. The calibration may be updated after evaluating the calibration set for best calibration based on inclusion criteria with newly received reference analyte data. Fail-safe mechanisms are provided based on clinical acceptability of reference and analyte data and quality of sensor calibration. Algorithms provide for optimized prospective and retrospective analysis of estimated blood analyte data from an analyte sensor.

公开(公告)号：US20100234707A1

公开(公告)日：2010-09-16

申请号：US12789153

申请日：2010-05-27

申请人： Paul V. Goode, JR. ,  James H. Brauker ,  Apurv U. Kamath ,  James Patrick Thrower ,  Victoria Carr-Brendel

发明人： Paul V. Goode, JR. ,  James H. Brauker ,  Apurv U. Kamath ,  James Patrick Thrower ,  Victoria Carr-Brendel

IPC分类号： A61B5/1473

CPC分类号： A61B5/7203 ,  A61B5/0004 ,  A61B5/0031 ,  A61B5/14532 ,  A61B5/14539 ,  A61B5/14542 ,  A61B5/1473 ,  A61B5/14865 ,  A61B5/1495 ,  A61B5/7225 ,  A61B5/7257 ,  A61B5/726 ,  A61B5/7278 ,  A61B5/742 ,  A61B5/7475 ,  A61B2560/0223 ,  A61B2562/0247 ,  A61B2562/0271 ,  A61B2562/08

摘要： Systems and methods for minimizing or eliminating transient non-glucose related signal noise due to non-glucose rate limiting phenomenon such as ischemia, pH changes, temperatures changes, and the like. The system monitors a data stream from a glucose sensor and detects signal artifacts that have higher amplitude than electronic or diffusion-related system noise. The system replaces some or the entire data stream continually or intermittently including signal estimation methods that particularly address transient signal artifacts. The system is also capable of detecting the severity of the signal artifacts and selectively applying one or more signal estimation algorithm factors responsive to the severity of the signal artifacts, which includes selectively applying distinct sets of parameters to a signal estimation algorithm or selectively applying distinct signal estimation algorithms.

公开(公告)号：US20100185065A1

公开(公告)日：2010-07-22

申请号：US12748144

申请日：2010-03-26

申请人： Paul V. Goode, JR. ,  James H. Brauker ,  Apurv U. Kamath ,  Victoria Carr-Brendel

发明人： Paul V. Goode, JR. ,  James H. Brauker ,  Apurv U. Kamath ,  Victoria Carr-Brendel

IPC分类号： A61B5/145

CPC分类号： A61B5/1495 ,  A61B5/14532 ,  A61B5/14542 ,  A61B5/14865 ,  A61B2560/0223 ,  G06F19/00

摘要： Systems and methods for processing sensor analyte data, including initiating calibration, updating calibration, evaluating clinical acceptability of reference and sensor analyte data, and evaluating the quality of sensor calibration. During initial calibration, the analyte sensor data is evaluated over a period of time to determine stability of the sensor. The sensor may be calibrated using a calibration set of one or more matched sensor and reference analyte data pairs. The calibration may be updated after evaluating the calibration set for best calibration based on inclusion criteria with newly received reference analyte data. Fail-safe mechanisms are provided based on clinical acceptability of reference and analyte data and quality of sensor calibration. Algorithms provide for optimized prospective and retrospective analysis of estimated blood analyte data from an analyte sensor.

公开(公告)号：US20100030053A1

公开(公告)日：2010-02-04

申请号：US12579385

申请日：2009-10-14

申请人： Paul V. Goode, JR. ,  James H. Brauker ,  Apurv U. Kamath ,  James Patrick Thrower ,  Victoria Carr-Brendel

发明人： Paul V. Goode, JR. ,  James H. Brauker ,  Apurv U. Kamath ,  James Patrick Thrower ,  Victoria Carr-Brendel

IPC分类号： A61B5/145 ,  G06F19/00

CPC分类号： A61B5/7203 ,  A61B5/0004 ,  A61B5/0031 ,  A61B5/14532 ,  A61B5/14539 ,  A61B5/14542 ,  A61B5/1473 ,  A61B5/14865 ,  A61B5/1495 ,  A61B5/7225 ,  A61B5/7257 ,  A61B5/726 ,  A61B5/7278 ,  A61B5/742 ,  A61B5/7475 ,  A61B2560/0223 ,  A61B2562/0247 ,  A61B2562/0271 ,  A61B2562/08

摘要： Systems and methods for minimizing or eliminating transient non-glucose related signal noise due to non-glucose rate limiting phenomenon such as ischemia, pH changes, temperatures changes, and the like. The system monitors a data stream from a glucose sensor and detects signal artifacts that have higher amplitude than electronic or diffusion-related system noise. The system replaces some or the entire data stream continually or intermittently including signal estimation methods that particularly address transient signal artifacts. The system is also capable of detecting the severity of the signal artifacts and selectively applying one or more signal estimation algorithm factors responsive to the severity of the signal artifacts, which includes selectively applying distinct sets of parameters to a signal estimation algorithm or selectively applying distinct signal estimation algorithms.

公开(公告)号：US20090124877A1

公开(公告)日：2009-05-14

申请号：US12353787

申请日：2009-01-14

申请人： Paul V. Goode, JR. ,  James H. Brauker ,  Apurv U. Kamath ,  James Patrick Thrower ,  Victoria Carr Brendel

发明人： Paul V. Goode, JR. ,  James H. Brauker ,  Apurv U. Kamath ,  James Patrick Thrower ,  Victoria Carr Brendel

IPC分类号： A61B5/00

CPC分类号： A61B5/7203 ,  A61B5/0004 ,  A61B5/0031 ,  A61B5/14532 ,  A61B5/14539 ,  A61B5/14542 ,  A61B5/1473 ,  A61B5/14865 ,  A61B5/1495 ,  A61B5/7225 ,  A61B5/7257 ,  A61B5/726 ,  A61B5/7278 ,  A61B5/742 ,  A61B5/7475 ,  A61B2560/0223 ,  A61B2562/0247 ,  A61B2562/0271 ,  A61B2562/08

摘要： Systems and methods for minimizing or eliminating transient non-glucose related signal noise due to non-glucose rate limiting phenomenon such as ischemia, pH changes, temperatures changes, and the like. The system monitors a data stream from a glucose sensor and detects signal artifacts that have higher amplitude than electronic or diffusion-related system noise. The system replaces some or the entire data stream continually or intermittently including signal estimation methods that particularly address transient signal artifacts. The system is also capable of detecting the severity of the signal artifacts and selectively applying one or more signal estimation algorithm factors responsive to the severity of the signal artifacts, which includes selectively applying distinct sets of parameters to a signal estimation algorithm or selectively applying distinct signal estimation algorithms.

摘要翻译： 用于最小化或消除由于非葡萄糖速率限制现象（如缺血，pH变化，温度变化等）引起的瞬时非葡萄糖相关信号噪声的系统和方法。 系统监测来自葡萄糖传感器的数据流，并检测具有比电子或扩散相关系统噪声更高的幅度的信号伪像。 该系统连续地或间歇地替代一些或整个数据流，包括特别地解决瞬态信号伪影的信号估计方法。 该系统还能够检测信号伪像的严重性并且响应于信号伪像的严重性选择性地应用一个或多个信号估计算法因子，其包括选择性地将不同的参数集合应用于信号估计算法或选择性地应用不同信号 估计算法。

公开(公告)号：US20090043542A1

公开(公告)日：2009-02-12

申请号：US12253120

申请日：2008-10-16

申请人： James H. Brauker ,  Victoria Carr-Brendel ,  Paul V. Goode ,  Apurv U. Kamath ,  James P. Thrower ,  Ben Xavier

发明人： James H. Brauker ,  Victoria Carr-Brendel ,  Paul V. Goode ,  Apurv U. Kamath ,  James P. Thrower ,  Ben Xavier

IPC分类号： G06F19/00

CPC分类号： A61B5/14532 ,  A61B5/145 ,  A61B5/14503 ,  A61B5/1451 ,  A61B5/1468 ,  A61B5/1473 ,  A61B5/1486 ,  A61B5/14865 ,  A61B5/1495 ,  A61B5/7257 ,  A61B5/726 ,  A61B5/7264 ,  A61B5/7275 ,  A61B5/742 ,  A61B5/7455 ,  A61B5/746 ,  A61B5/7475 ,  A61M5/1723 ,  G06F19/00 ,  Y02A90/22 ,  Y02A90/26

摘要： Systems and methods for dynamically and intelligently estimating analyte data from a continuous analyte sensor, including receiving a data stream, selecting one of a plurality of algorithms, and employing the selected algorithm to estimate analyte values. Additional data processing includes evaluating the selected estimative algorithms, analyzing a variation of the estimated analyte values based on statistical, clinical, or physiological parameters, comparing the estimated analyte values with corresponding measure analyte values, and providing output to a user. Estimation can be used to compensate for time lag, match sensor data with corresponding reference data, warn of upcoming clinical risk, replace erroneous sensor data signals, and provide more timely analyte information encourage proactive behavior and preempt clinical risk.

公开(公告)号：US20080195232A1

公开(公告)日：2008-08-14

申请号：US12103594

申请日：2008-04-15

申请人： Victoria Carr-Brendel ,  Peter C. Simpson ,  James H. Brauker

发明人： Victoria Carr-Brendel ,  Peter C. Simpson ,  James H. Brauker

IPC分类号： A61F2/02 ,  A61B5/145 ,  A61M5/14

CPC分类号： A61L31/10 ,  A61L31/146 ,  A61L31/16 ,  A61L2300/10 ,  B33Y80/00

摘要： Disclosed herein are biointerface membranes including a macro-architecture and a micro-architecture co-continuous with and bonded to and/or located within at least a portion of the macro-architecture. The macro- and micro-architectures work together to manage and manipulate the high-level tissue organization and the low-level cellular organization of the foreign body response in vivo, thereby increasing neovascularization close to a device-tissue interface, interfering with barrier cell layer formation, and providing good tissue anchoring, while reducing the effects of motion artifact, and disrupting the organization and/or contracture of the FBC. The biointerface membranes of the preferred embodiments can be utilized with implantable devices such as devices for the detection of analyte concentrations in a biological sample (for example, from a body), cell transplantation devices, drug delivery devices, electrical signal delivering or measuring devices, and/or combinations thereof.

摘要翻译： 本文公开的是生物界面膜，其包括宏观架构和与宏结构共同连接并连接到宏结构和/或位于宏观架构的至少一部分内的微架构。 宏观和微观结构共同协调管理和操纵体内异物反应的高级别组织结构和低水平细胞组织，从而增加接近装置 - 组织界面的新生血管形成，干扰屏障细胞层 形成并提供良好的组织锚定，同时减少运动神经的影响，并破坏FBC的组织和/或挛缩。 优选实施方案的生物界面膜可以与可植入装置一起使用，例如用于检测生物样品（例如，来自身体），细胞移植装置，药物递送装置，电信号传送或测量装置中的分析物浓度的装置， 和/或其组合。